|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Clevidipine#Patient Counseling Information]] |
| {{Clevidipine}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Patient Counseling Information==
| |
| | |
| *Advise patients with underlying [[hypertension]] that they require continued follow up for their medical condition, and, if applicable, encourage patients to continue taking their oral antihypertensive medication(s) as directed.
| |
| *Advise patients to contact a healthcare professional immediately for any of the following signs of a new hypertensive emergency: neurological symptoms, visual changes, or evidence of congestive heart failure.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CLEVIPREX (CLEVIDIPINE) EMULSION [THE MEDICINES COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=095081a0-1398-11dc-82e1-0002a5d5c51b | publisher = | date = | accessdate = 27 February 2014 }}</ref>
| |
| | |
| ==References ==
| |
| {{Reflist|2}}
| |
| | |
| {{Calcium channel blockers}}
| |
| | |
| [[Category:Calcium channel blockers]]
| |
| [[Category:Dihydropyridines]]
| |
| [[Category:Organochlorides]]
| |
| [[Category:Carboxylate esters]]
| |
| [[Category:Butyrates]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |